Oppenheimer & Co. Inc. lessened its holdings in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 2.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,170 shares of the medical research company’s stock after selling 84 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Charles River Laboratories Intl. were worth $450,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Flagship Harbor Advisors LLC grew its holdings in Charles River Laboratories Intl. by 132.1% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after buying an additional 181 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new stake in shares of Charles River Laboratories Intl. during the second quarter valued at approximately $69,000. Machina Capital S.A.S. bought a new stake in shares of Charles River Laboratories Intl. during the second quarter valued at approximately $72,000. Hilton Capital Management LLC purchased a new position in shares of Charles River Laboratories Intl. in the first quarter worth $118,000. Finally, Cigna Investments Inc. New bought a new position in shares of Charles River Laboratories Intl. during the first quarter worth $201,000. 94.40% of the stock is currently owned by institutional investors.

Several equities analysts recently weighed in on CRL shares. Leerink Swann started coverage on shares of Charles River Laboratories Intl. in a research note on Monday, June 10th. They set an “outperform” rating for the company. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday. Finally, Svb Leerink started coverage on Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating and a $155.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $147.62.

In related news, insider David Ross Smith sold 1,249 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $130.36, for a total value of $162,819.64. Following the transaction, the insider now owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a filing with the SEC, which is available through this link. 1.80% of the stock is owned by corporate insiders.

Shares of NYSE CRL traded up $1.26 during midday trading on Wednesday, reaching $130.94. The company had a trading volume of 4,343 shares, compared to its average volume of 233,653. The company has a current ratio of 1.59, a quick ratio of 1.38 and a debt-to-equity ratio of 1.47. The business’s 50-day simple moving average is $132.09 and its 200 day simple moving average is $136.35. Charles River Laboratories Intl. Inc has a 1 year low of $103.00 and a 1 year high of $149.07. The stock has a market cap of $6.35 billion, a P/E ratio of 21.62, a P/E/G ratio of 1.66 and a beta of 1.09.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 EPS for the quarter, topping the Zacks’ consensus estimate of $1.55 by $0.08. The company had revenue of $657.60 million during the quarter, compared to analysts’ expectations of $662.61 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The firm’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.62 EPS. Analysts predict that Charles River Laboratories Intl. Inc will post 6.52 earnings per share for the current year.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: Golden Cross

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.